In our study we looked in retrospect, whether the immunohistochemical expression of TS and Topo I (which is the target of irinotecan) had any predictive significance in a large cohort of patients with colorectal cancer, who received several schedules of 5-FU-based adjuvant chemotherapy. This evidence concerns the gene TYMS and colorectal cancer.